A biopharmaceutical company pioneering the discovery of novel payload mechanisms for antibody-drug conjugates (ADCs)
hexagonbio.comLinkedInMenlo Park, CABiotechFounded 2016
4 sources · checked 1 time, last 1h ago
2 sources
2 sources
The sources do not state a round stage or valuation. “MENLO PARK, CA” is a dateline, not a stated headquarters.
1 source
Developing: it holds up against its sources so far, and firms up as more reporting lands.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series C | $62M | 2026-10-23 | The Column Group | 2 outlets. #76 in Trending |
4 sources · checked 1 time, last 1h ago [ VERIFIED ] read against 2 of 4 sources | ||||
Hexagon Bio discovers and develops novel payload mechanisms for antibody-drug conjugates (ADCs) to help cancer therapies overcome resistance and reach more solid tumors.
Existing ADC payloads are constrained by toxicity and acquired resistance, while Hexagon says its novel translation-inhibitor payloads are designed to bypass those resistance mechanisms and broaden targeted treatment to solid tumors. Its $62 million Series C is funding a first-in-human Phase 1 study of HEX-360 expected in the first half of 2027 and additional payload programs, turning the platform bet toward clinical validation.
Checked against 10 sources today
| Series B [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $77.3M | 2023-02-13 | not stated | No recent discussion |
2 sources [ VERIFIED · CORRECTED ] read against 1 of 2 sources [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]2 pages read: hexagonbio.com, globenewswire.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 of 2 sources·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent | ||||
| Funding round [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $61M $108M to date | 2021-09-22 | Nextech Invest | No recent discussion |
2 sources [ VERIFIED · CORRECTED ] read against 2 sources The sources do not state a round stage or valuation. “MENLO PARK, CA” is a dateline, not a stated headquarters. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]2 pages read: hexagonbio.com, businesswire.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 2 sources·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent | ||||
| Series A [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $47M | 2020-09-15 | The Column Group | No recent discussion |
1 source [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 source [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: hexagonbio.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]confirmedchecked against 1 source·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent | ||||